Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 875 versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 875 versus NALLPEN.
AUGMENTIN '875' vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic